Separation of growth inhibiting potency from oestrogenicity in different weak oestrogenic drugs of various chemical structures.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001835:Body Weight; D002356:Cartilage / Q000502:physiology; D002741:Chlorotrianisene / Q000494:pharmacology; D003510:Cyclohexanes / Q000494:pharmacology; D004357:Drug Synergism; D004958:Estradiol / Q000494:pharmacology; D004967:Estrogens / Q000494:pharmacology*; D005260:Female; D006130:Growth Disorders / Q000139:chemically induced*; D007279:Injections, Subcutaneous; D009281:Naphthalenes / Q000494:pharmacology; D010053:Ovary / Q000601:surgery; D012632:Secosteroids / Q000494:pharmacology; D012737:Sex Factors; D013431:Sulfates / Q000037:antagonists & inhibitors / Q000378:metabolism; D013460:Sulfur Isotopes; D014316:Tritium; D014599:Uterus / Q000187:drug effects
D000970:Antineoplastic Agents; D003510:Cyclohexanes; D004967:Estrogens; D009281:Naphthalenes; D012632:Secosteroids; D013431:Sulfates; D013460:Sulfur Isotopes; D014316:Tritium; D004958:Estradiol; D002741:Chlorotrianisene